Edgewise Therapeutics, Inc.
EWTX
Pozycja w akcjach
#3982
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Cena akcji
$38.12
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$4.10B
Zmiana (1 dzień)
2.50%
Zmiana (1 rok)
147.69%
Kraj
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategoria
Healthcare
Wskaźnik P/S dla Edgewise Therapeutics, Inc. (EWTX)
Wskaźnik P/S na dzień October 2026 TTM: 0.00
Według najnowszych raportów finansowych i ceny akcji Edgewise Therapeutics, Inc., obecny wskaźnik P/S (TTM) wynosi 0.00. Na koniec 2023 wynosił 0.00.
Historia wskaźnika P/S dla Edgewise Therapeutics, Inc. od 2019 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
